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Abstract
Changes in FKBP12.6 binding to cardiac ryanodine receptors (RyR2) are implicated in mediating disturbances in Ca
2+-
homeostasis in heart failure but there is controversy over the functional effects of FKBP12.6 on RyR2 channel gating. We
have therefore investigated the effects of FKBP12.6 and another structurally similar molecule, FKBP12, which is far more
abundant in heart, on the gating of single sheep RyR2 channels incorporated into planar phospholipid bilayers and on
spontaneous waves of Ca
2+-induced Ca
2+-release in rat isolated permeabilised cardiac cells. We demonstrate that FKBP12 is
a high affinity activator of RyR2, sensitising the channel to cytosolic Ca
2+, whereas FKBP12.6 has very low efficacy, but can
antagonise the effects of FKBP12. Mathematical modelling of the data shows the importance of the relative concentrations
of FKBP12 and FKBP12.6 in determining RyR2 activity. Consistent with the single-channel results, physiological
concentrations of FKBP12 (3 mM) increased Ca
2+-wave frequency and decreased the SR Ca
2+-content in cardiac cells.
FKBP12.6, itself, had no effect on wave frequency but antagonised the effects of FKBP12. We provide a biophysical analysis
of the mechanisms by which FK-binding proteins can regulate RyR2 single-channel gating. Our data indicate that FKBP12, in
addition to FKBP12.6, may be important in regulating RyR2 function in the heart. In heart failure, it is possible that an
alteration in the dual regulation of RyR2 by FKBP12 and FKBP12.6 may occur. This could contribute towards a higher RyR2
open probability, ‘leaky’ RyR2 channels and Ca
2+-dependent arrhythmias.
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Introduction
The cardiac ryanodine receptor (RyR2) is the main pathway for the
release of intracellular Ca
2+ during excitation-contraction (EC)
coupling in cardiac muscle [1]. Several studies have shown that
FKBP12.6, a member of the FK506-binding protein family, binds
with high affinity to RyR2 [2–4] but the functional consequences of
this interaction has remained a highly controversial subject. The
dissociation of FKBP12.6 from RyR2 has been linked with heart
failure and arrhythmia generation [5,6] and it has been proposed that
the ensuing dysfunctional RyR2 channel behaviour contributes to the
defective Ca
2+ homeostasis that is characteristic of heart failure [7]. A
maximum of four FKBP12.6 molecules is thought to bind each RyR2
tetramer [2]. The dissociation of FKBP12.6 from RyR2 has been
reported to induce marked changes to RyR2 function which include
pronounced sub-conductance state gating, high open probability (Po)
and channel gating that is unregulated by Ca
2+[5,8,9]. On the basis of
this work, FKBP12.6 has become widely accepted as a ‘stabiliser’ of
RyR2 channel function but there is an underlying impression that this
is an over-simplification of the role of FKBP12.6 as some investigators
find that FKBP12.6 appears not to influence RyR2 gating [10–12].
Cellular studies are more unanimous in pointing towards a
cardioprotective role for FKBP12.6. Many studies indicate that
FKBP12.6 does ‘stabilise’ or reduce sarcoplasmic reticulum (SR)
Ca
2+-release [5,13–16], and it appears to provide a protective role
that becomes altered in heart failure [7,14]. Cardiac cells derived
from FKBP12.6 knockout mice show altered Ca
2+-spark charac-
teristics when compared to wild type cells with the amplitude, size
and duration of sparks being significantly increased and the gain of
Ca
2+-induced Ca
2+-release elevated [17].
In contrast to FKBP12.6, there has been less emphasis on the
cardiac role of FKBP12. However, the FKBP12 knockout mouse is
characterised by severe dilated cardiomyopathy and the RyR2
channels isolated from this model exhibit unusual gating
behaviour governed by long-lived sub-conductance state openings
[18]. Moreover, Seidler et al. (2007) demonstrate that GST-
FKBP12 binds tightly to RyR2 and that overexpression of
FKBP12 causes alterations to the characteristics of Ca
2+-sparks.
These results suggested to us that FKBP12 might have a more
important cardiac role than previously envisaged, and that a
primary target of its action may be RyR2. It is especially
interesting therefore, that FKBP12 is thought to be present at
much higher concentrations than FKBP12.6 in cardiac cells
[2,19]. FKBP12 shares 85% sequence homology with FKBP12.6
and crystallographic studies show very high structural homology
[20–22] highlighting the possibility that FKBP12 and FKBP12.6
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therefore investigated the ability of FKBP12 and FKBP12.6 to
modulate the single-channel function of RyR2 and affect waves of
spontaneous Ca
2+-induced Ca
2+-release (CICR) in isolated cardiac
cells. We demonstrate the novel ability of FKBP12 to activate
RyR2. Importantly, FKBP12.6 can antagonise activation of RyR2
by FKBP12 and our data suggest that FKBP12.6 may be a partial
agonist with negligible efficacy at RyR2. Our results suggest that
FKBP12 and FKBP12.6 can regulate the gating of RyR2 by
modulating the sensitivity of the channel to cytosolic Ca
2+.
Methods
Isolation of membrane fractions and planar phospholipid
bilayer techniques
Mixed membrane (MM) vesicles were prepared from sheep
hearts (obtained from a local abbatoir), as described previously
[23]. In brief, homogenised ventricular tissue was subjected to
centrifugation at 65006 g followed by ultracentrifugation of the
supernatant at 100,0006 g. Following this spin, both the
sedimented MM pellet and the supernatant (S2) were retained
for detection of FKBPs. The MM pellet was resuspended with a
solution containing 0.4 M KCl to remove remaining FKBPs and
the heavy SR membrane fraction was obtained from a
discontinuous sucrose-density gradient, snap frozen in liquid N2,
and stored at 280uC as previously described [23]. SR vesicles
were fused with planar phosphatidylethanolamine lipid bilayers as
described previously [23]. The SR vesicles fused in a fixed
orientation such that the cis-chamber corresponded to the cytosolic
space and the trans-chamber to the SR lumen. The trans-chamber
was held at ground and the cis-chamber held at potentials relative
to ground. After fusion, the cis-chamber was perfused with
250 mM HEPES, 80 mM Tris, 10 mM free Ca
2+, pH 7.2, unless
stated otherwise. The trans-chamber was perfused with 250 mM
glutamic acid and 10 mM HEPES, pH to 7.2 with Ca(OH)2 (free
[Ca
2+], approximately 50 mM). Experiments were carried out at
room temperature (2262uC). The identity of the channels was
confirmed by the single-channel conductance and the application
of caffeine at the end of the experiment. The free [Ca
2+] and pH
of the solutions were determined using a Ca
2+ electrode (Orion 93-
20) and a Ross-type pH electrode (Orion 81-55) as previously
described [23]. After addition of 10 mM EGTA to the cis-
chamber, the approximate free [Ca
2+] was calculated using the
program MaxChelator (www.stanford.edu/,cpatton/maxc.html)
as 1 nM. The pH of the solutions was maintained constant.
Additions of FKBP12 and FKBP12.6 were made to the cis-
chamber. Both proteins were stored in a buffer containing 10 mM
HEPES/50 mM NaCl, 0.5 mM DTT and volumes added to the
cis-chamber were ,2% of the total volume. Control buffer
solution did not alter Po.
Data acquisition and Analysis
Channel recordings were displayed on an oscilloscope and
recorded on digital audiotape (DAT). Current recordings were
filtered at 800 Hz (23 dB) and digitised at 20 kHz using Pulse
(HEKA, Elektronik Lambrecht/Pfalz, Germany). Channel open
probability (Po) was determined over $3 min of continuous
recording, unless otherwise stated, using the method of 50%
threshold analysis [24]. Lifetime analysis was carried out only
when a single channel incorporated into the bilayer. Events ,1m s
in duration were not fully resolved and were excluded from
lifetime analysis. Individual lifetimes were fitted to a probability
density function (pdf) by the method of maximum likelihood
according to the equation:
g(x)~
X N
i~1
aigo(x{lnti)
where lntI is the logarithm of the ith time constant and ai is the
fraction of the total events represented by that component [25].
Cardiac myocyte isolation and measurement of Ca
2+
waves in rat permeabilised myocytes
Male Wistar rats were killed by cervical dislocation in
accordance with the Animal (Scientific Procedures) Act 1986.
Rat ventricular myocytes were isolated using a protease and
collagenase Langendorff perfusion technique as previously de-
scribed [26]. Cells were incubated with 0.1 mgml
21 b-escin for
1 min to permeabilise the surface membrane as previously
described [27]. The b-escin was removed by hand-centrifugation.
After permeabilisation myocytes were resuspended in a mock
intracellular solution composed of (mM): 100 KCl, 5 Na2ATP, 5.4
MgCl2, 25 Hepes, 0.1 K2EGTA, pH 7.0 at 37uC for 5 min. This
was to encourage dissociation of endogenous FK-binding proteins
from RyR2 as it has been shown that FK-binding proteins
dissociate quickly at 37uC [2]. Spontaneous waves of CICR were
measured by adding 10 mM Fluo-5F to the mock intracellular
solution and raising the [Ca
2+] to 234 nM. The waves were
recorded at 21uC using a laser-scanning confocal microscope
(BioRad MRC 1024) in the linescan mode. Linescan images were
analyzed using ImageJ software (wsr@nih.gov). Waves of CICR
were thus monitored in each cell before and after the addition of
either 3 mM FKBP12 or 200 nM FKBP12.6 to the mock
intracellular solution. For experiments to test the ability of
FKBP12.6 to antagonize FKBP12, cells were first incubated with
200 nM FKBP12.6 for 5 min at 21uC and subsequently perfused
with 3 mM FKBP12 in the continued presence of FKBP12.6. The
SR Ca
2+-content was examined in the absence and in the presence
of FKBP12 after application of caffeine (20 mM) to release Ca
2+
stores into the cytosol.
Cloning, expression and purification of FK-506 binding
proteins
Recombinant DNA techniques were carried out according to
standard protocols. The FKBP12 and 12.6 proteins were
constructed by PCR amplification using the pCMV6-XL4-true
clone (OriGene Technologies, Rockville, USA) and the PGEX-
4T-1 vector (Addgene, Cambridge, USA) respectively. The two
constructs were subcloned in the pET-28a plasmid (Novagen,
USA) and transformed in Escherichia coli BL21(DE3) Codon Plus
cells (Stratagene, CA, USA). Protein expression was induced by
addition of Isopropyl-b-D-1-thiogalactopyranoside (IPTG 1 mM)
to the culture. After 3 hours, cells were pelleted, resuspended in
Tris-buffer (10 mM Tris-HCl, 5 mM b-mercaptoethanol, 1 mM
EDTA), and lysed by sonication to obtain soluble protein. The
protein extracts were purified by cation exchange and size
exclusion chromatography using an HPLC-AKTA machine (GE
healthcare, Buckinghamshire, UK). The filtered proteins were
loaded in a CM Sepharose Fast Flow column (GE healthcare,
Buckinghamshire, UK) in Tris-buffer, pH 6.8 and pH 6.6
respectively for FKBP12.6 and FKBP12, and eluted by a linear
NaCl gradient. The proteins were subsequently purified by gel
filtration using a Superdex 75 10/300 GL column (GE healthcare,
Buckinghamshire, UK) in a buffer containing 10 mM HEPES,
50 mM NaCl, 0.5 mM DTT, pH 8. The purified chromato-
graphic peaks were checked by SDS-polyacrylamide gel electro-
phoresis. The high-quality samples were mixed and concentrated
with Amicon 10 kDa Ultra-4 Centrifugal Filter Units (Millipore,
RyR2 Is Regulated by FKBP12 and FKBP12.6
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concentration of FKBP12 and FKBP12.6 was calculated by a
Bradford assay [28] and both the quality and the identity of the
proteins were validated by Mass Spectrometry and N-terminal
sequencing. FKBP12 was also purchased from Sigma-Aldrich
(Dorset, UK).
Western Blotting
The protein concentration of the vesicles was calculated by a
Bradford assay. Proteins were then size fractionated by SDS-
PAGE on either a 4–20% precast gel (BioRad, Hertfordshire, UK)
or a 15% gel. Following separation, proteins were transferred to a
nitrocellulose membrane and non-specific binding sites were
blocked for 1 hr at room temperature using 5% dried milk and
Tris-buffered saline, 0.1% Tween 20, pH 7.4. Membranes were
probed for 2 h at room temperature with a polyclonal primary
anti-FKBP antibody ((1:500) Thermo Fisher Scientific, Leicester-
shire, UK)). A secondary horseradish peroxidase linked anti-rabbit
IgG ((1:5000) GE Healthcare, Buckinghamshire, UK)) was used in
combination with an enhanced chemiluminescent detection
system (GE Healthcare, Buckinghamshire, UK) to visualise the
primary antibodies.
Detection and identification of FKBP12 and FKBP12.6 in
sheep heart
During the procedure for isolation of heavy SR membrane
vesicles from sheep cardiac muscle, the MM vesicle fraction, the
corresponding supernatant (termed S2; see above) and the heavy
SR vesicles were collected and electrophoresed on a 15% SDS-
PAGE. Prior to electrophoresis, the supernatant (S2) was filtered
multiple times, each time reducing the pore of the filter from
1.2 mM–0.22 mM and concentrated by centrifugation at 35006g
for 15 h with an Amicon 10 kDa Ultra-15 centrifugal filter unit
(Millipore, Watford, UK). Following separation, the proteins were
either visualised by staining with Coomassie brilliant blue (CBB) or
transferred to a nitrocellulose membrane for Western blot analysis.
Where anti-FKBP antibodies indicated the presence of FKBPs on
the Western blot, the corresponding band visualised by CBB
staining was cut from the gel. The gel slice was subjected to in-gel
tryptic digestion using a ProGest automated digestion unit (Digilab
UK). The resulting peptides were fractionated using a Dionex
Ultimate 3000 nanoHPLC system. In brief, peptides in 1% (v/v)
formic acid were injected onto an Acclaim PepMap C18 nano-
trap column (Dionex-Thermo Fisher Scientific, Leicestershire,
UK). After washing with 0.5% (v/v) acetonitrile 0.1% (v/v) formic
acid peptides were resolved on a 250 mm675 mm Acclaim
PepMap C18 reverse phase analytical column (Dionex-Thermo
Fisher Scientific, Leicestershire, UK) over a 120 min organic
gradient with a flow rate of 300 nlmin
21. Peptides were ionized by
nano-electrospray ionization at 2.3 kV using a stainless steel
emitter with an internal diameter of 30 mm (Proxeon-Thermo
Fisher Scientific, Leicestershire, UK). Tandem mass spectrometry
analysis was carried out on a LTQ-Orbitrap Velos mass
spectrometer (Thermo Fisher Scientific, Leicestershire, UK). The
Orbitrap was set to analyze the survey scans at 60,000 resolution
and the top twenty ions in each duty cycle selected for MS/MS in
the LTQ linear ion trap. Data was acquired using the Xcalibar
v2.1 software (Thermo Fisher Scientific, Leicestershire, UK). The
raw data files were processed and quantified using Proteome
Discoverer software v1.2 (Thermo Fisher Scientific, Leicestershire,
UK) with searches performed against the UniProt human database
by using the SEQUEST algorithm with the following criteria;
peptide tolerance=10 ppm, trypsin as the enzyme, carboxyami-
domethylation of cysteine as a fixed modification and the
oxidation of methionine as a variable modification. The reverse
database search option was enabled and all data was filtered to
satisfy false discovery rate (FDR) of less than 5%.
Computations
Monte Carlo simulations of the two-state RyR ion channel
model were performed using XPPAUT (www.math.pitt.edu/
,bard/xpp/xpp.html). Steady state Po was computed by taking
the trial average of 100 simulations of one channel. For plott-
ing the modelling results we used IGOR Pro (http://www.
wavemetrics.com/).
Statistics
Data are expressed as mean 6 SEM where n$4. For n=3, SD
is given. Where appropriate, Student’s t-test was used to assess the
difference between treatments. Where multiple treatments were
compared, ANOVA followed by a modified t-test was used to
assess the difference between treatments. A p value of ,0.05 was
taken as significant.
Materials
Escin was obtained from Sigma-Aldrich (Dorset, UK). Fluo-5F
was obtained from Invitrogen, (Paisley, UK). Other chemicals
were AnalaR or the best equivalent grade from BDH (Poole, UK)
or Sigma-Aldrich (Dorset, UK). All solutions were made in
deionised water and those for use in bilayer experiments were
filtered through a Millipore membrane filter (0.45 mm pore).
Results
Effects of FK-binding proteins on RyR2 single channel
function
The endogenous FKBPs associated with RyR2 were dissociated
by high salt incubation during the sucrose gradient step of the
heavy SR isolation procedure (see Figure S1). For single-channel
studies this treatment is preferable to treatment with drugs such as
rapamycin or FK-506 as we found, in line with other investigators
[29,30], that these compounds produced direct and irreversible
effects on RyR2 channel gating (results not shown) that were not
related to the dissociation of FKBPs. Figure 1A demonstrates that
FKBPs are not detected in the heavy SR membrane fraction but
also illustrates that most of the FKBPs are not associated with
RyR2 but are present in the supernatant of the second spin (which
is normally discarded). To determine the identity of the FKBPs
present in sheep cardiac muscle, where FKBPs were detected by
Western blot analysis, we subjected the same samples (supernatant
of the second spin (S2) and the MM vesicles) to electrophoresis
using an SDS-polyacrylamide gel under identical conditions to the
Western blot. Following CBB staining, these bands were cut out
and sequenced using mass spectrometry as described in the
Methods. In both the supernatant of the second spin (S2) and in
the MM vesicles, FKBP12 was detected with high confidence (false
discovery rate ,1%). FKBP12.6 was detected in both fractions
with lower confidence (.5%).
The FKBP-depleted SR was then incorporated into bilayers and
two typical experiments are shown, illustrating that neither a low
(Figure 1B) nor a high (Figure 1C) concentration of FKBP12.6
produced any decrease in Po and that no large changes in gating
behaviour could be detected. Notice that there are no obvious sub-
conductance gating states (before or after addition of FKBP12.6),
although filtering the data causes truncation of the very brief
events. The physiological levels of FKBP12.6 are not known but
are thought to be very low in cardiac cells [2,3,10]. Over a wide
range of concentrations, likely to encompass the physiological
RyR2 Is Regulated by FKBP12 and FKBP12.6
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Po although this was only significant at 200 nM (Po increased
from 0.0660.01 to 0.1260.02 (SEM; n=12; p,0.05)). RyR
channels are known to exhibit a large variation in their Po levels
[31–34] and therefore to investigate if variation in the control Po
could mask any small effects of FKBP12.6, we subtracted the
control Po of each channel from the Po obtained in the presence of
FKBP12.6. Figure 1D illustrates this analysis showing that if the
variability in control Po is corrected for, there appears to be a
trend towards a very slight increase in Po.
Although cardiac FKBP12.6 levels are extremely low, FKBP12
is present at much higher concentrations (1–3 mM) [3,10].
Figure 2A shows a typical experiment illustrating that a
physiological concentration of FKBP12 is very effective as an
activator of RyR2. We found that even very low concentrations of
FKBP12 (1 pM) could activate RyR2 (see Figure 2B) indicating
that FKBP12 has high affinity for RyR2. 1 pM FKBP12 increased
Po from 0.0460.008 to 0.2360.04 (SEM; n=6; **p,0.01).
FKBP12 was not able to fully open the channel at any
concentration (Figure 2C) indicating that FKBP12 is a partial
agonist of RyR2 but with much greater efficacy than FKBP12.6.
As with the FKBP12.6 data (Figure 2C), to remove any possible
dependence on the starting Po level, we subtracted the control Po
of each channel so that only the increase in Po is compared for
each concentration of FKBP12.
The fact that a wide range of FKBP12 concentrations produce
similar increases in Po indicates that when a molecule/s of
FKBP12 binds to RyR2, it binds very tightly and dissociates
slowly. If this is the case, we would expect Po to remain high after
washout of FKBP12 from the cytosolic chamber. Where possible
(because bilayers often break with perfusion), we therefore
recorded for long periods (9 min) after washing out the FKBP12
in order to investigate if dissociation of FKBP12 from RyR2 could
be detected by a sudden drop in Po. Figure 3 shows examples of
the time-dependence of Po that was observed after incubating
RyR2 in the presence of low (1 pM), medium (200 nM) or high
(1 mM) concentrations of FKBP12. Po was measured in 10 s
segments. The mean steady-state Po change for the indicated
FKBP12 concentration is shown in the bar charts. RyR2 is known
to exhibit modal gating [32,35] and this was very obvious both in
the control records and after addition of FKBP12. Modal gating
was also evident following washout of FKBP12 but in the majority
of experiments, there were no obvious changes in Po that could
signal the sudden dissociation of FKBP12 from RyR2 (see first
three examples of Po time plots). Sometimes after washout, the
average Po was slightly lower than in the presence of FKBP12 (see
plots 1 and 3) but was still higher than the control (before addition
of FKBP12). In only 3 out of 17 washout experiments did Po
appear to completely reverse back to control values following
FKBP12 washout (see example in bottom panel). These variable
changes in Po following FKBP12 washout suggest that dissociation
of FKBP12 from RyR2 is a slow process (of the order of minutes)
that is difficult to observe within the timescale of a single-channel
experiment.
Since FKBP12.6 appears to have very little ability to activate
RyR2 and since FKBP12 and FKBP12.6 are extremely similar
structurally, it is possible that FKBP12.6 could act as an antagonist
of FKBP12. Cryo-electron microscopy and 3D reconstruction of
RyR1 indicates that FKBP12 and FKBP12.6 bind within the same
location on the cytoplasmic face of RyR1 [36–38] providing
evidence that FKBP12 and FKBP12.6 could compete for the same
binding site/s on RyR channels. If this is the case, then the binding
of FKBP12.6 to RyR2 should reduce the effectiveness of FKBP12
as an activator of RyR2. Figure 4A shows the time dependence of
Figure 1. The effects of FKBP12.6 on RyR2 gating. (A) Western
blot analysis of the supernatant (left gel) and sedimented cardiac mixed
membrane vesicles (left lane of right gel) and heavy SR vesicles (right
lane of right gel). Vesicles were loaded onto 15% gels at 1 mg. Western
blots were probed with an anti-FKBP12 antibody (recognising both
FKBP12 and FKBP12.6). Size markers are indicated in kDa. Two
representative single-channel experiments are shown. One experiment
illustrates the typical effects of 10 nM FKBP12.6 (B) and the other
illustrates the effect of a concentration of FKBP12.6 (200 nM) that is
expected to be higher than the physiological level (C). The dotted lines
indicate the open (O) and closed (C) channel levels respectively. (D) The
relationship between FKBP12.6 concentration and Po is shown. The Po
is expressed as the increase in Po above the control level (for each
channel, the control Po was subtracted from the Po in the presence of
FKBP12.6). Error bars show the mean values 6SEM (n$4).
doi:10.1371/journal.pone.0031956.g001
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first added to the cytosolic channel side and this was followed by
incremental additions of FKBP12. In the presence of FKBP12.6,
FKBP12 was not able to activate the channel to such a high Po as
in the absence of FKBP12.6 (notice that the Po axis is highly
expanded so that the very low Po levels can be tracked). The mean
data in Figure 4C demonstrates that preincubation of RyR2 with
FKBP12.6 significantly reduces the ability of FKBP12 to activate
RyR2 as expected if FKBP12.6 is acting as an antagonist of
FKBP12.
Our washout data (Figure 3) suggests that once bound, FKBP12
dissociates slowly from RyR2. It would be expected therefore,
that if FKBP12 and FKBP12.6 compete for the same sites,
FKBP12.6 would be unable to access the binding sites if the
channels were first pre-bound with FKBP12. We therefore
performed experiments where FKBP12 was added before adding
FKBP12.6. The results of a typical experiment are shown in
Figure 4B and the mean Po levels are given in Figure 4D. In line
with our hypothesis, the addition of FKBP12.6 did not
immediately lower RyR2 Po.
To investigate the mechanisms underlying RyR2 activation by
FKBP12 we performed lifetime analysis on experiments where
only a single channel was gating in the bilayer. [In most
experiments, multiple channels incorporated in the bilayer and
these experiments were used for Po measurements but lifetime
analysis could not be performed]. The mean open time was
1.0160.04 ms in the absence and 1.8260.24 ms (n=6; SEM) in
the presence of 1 mM FKBP12 and the mean closed time was
27.9469.98 ms in the absence and 6.9361.32 ms (n=6; SEM)
in the presence of 1 mM FKBP12. Thus FKBP12 primarily
affected the duration of the closed times. This mechanism was
confirmed by lifetime analysis and examples of representative
open and closed lifetime histograms for control and FKBP12
treated channels are shown in Figure 5. The best fit to control data
was obtained with three exponentials to the closed lifetime
distribution and two exponentials to the open lifetime distribution
indicating at least three closed states and two open states [39,40].
FKBP12 reduced the duration of all the closed states and
increased the proportion of events occurring to the shortest
time constant whereas little change in duration of the openings
could be detected. Thus, FKBP12 primarily increases Po by
increasing the frequency of channel openings. We have
previously demonstrated that this is also the mechanism by
which cytosolic Ca
2+ activates RyR2 and the mechanism by which
agents such as caffeine that ‘‘sensitise’’ RyR2 to the effects of
cytosolic Ca
2+ appear to increase Po [41]. Hence, it is likely
that FKBP12 is increasing Po by sensitising the channel to
cytosolic Ca
2+.
If this is the mechanism by which FKBP12 activates RyR2, then
FKBP12 will not activate RyR2 in the absence of activating levels
of cytosolic Ca
2+. We found that this was indeed the case. If the
cytosolic [Ca
2+] was lowered to approximately 1 nM by addition
of 10 mM EGTA, then Po was reduced to zero (Po=0; n=4).
After addition of 1 mM FKBP12, Po remained at zero (n=4).
Similarly, if cytosolic Ca
2+ was reduced to approximately 1 nM
following channel activation by FKBP12 in the presence of
micromolar cytosolic Ca
2+, the channels could be completely shut
down. An example of this behaviour can be seen in Figure 3 (third
Po time-plot; indicated by ‘EGTA’) where a channel that has been
activated by FKBP12 can be closed by lowering cytosolic Ca
2+ to
sub-activating (approximately 1 nM) levels.
Modelling the effects of FK-binding proteins on RyR2
channel gating
We constructed a kinetic model to describe the possible channel
states and the transitions between states that arise from the binding
of FKBP12 or FKBP12.6 to RyR2. We then used this model to
simulate our data. We assume the simplest case; that RyR2 can
exist in the FKBP-free state (RyR2Free) and that it can bind
FKBP12 or FKBP12.6 forming either the FKBP12 bound state
(RyR212) or the FKBP12.6 bound state (RyR212.6). Each binding
event leads to a conformational change in RyR2, which in turn
modifies channel function in a manner specific to the isoform of
FKBP that is bound. Thus, when FKBP12 is bound, the Ca
2+-
Figure 2. The effect of FKBP12 on RyR2 gating. Two typical
single-channel experiments demonstrating that addition of either 1 mM
(A) or 1 pM (B) cytosolic FKBP12 causes a marked increase in channel
Po. The dotted lines indicate the open (O, O1,O 2) and closed (C) channel
levels. (C) The relationship between FKBP12 concentration and Po is
shown. Po is expressed as the increase in Po above the control level (for
each channel, the control Po was subtracted from the Po in the
presence of FKBP12). Error bars show the mean values 6SEM (n=4–17).
doi:10.1371/journal.pone.0031956.g002
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FKBP12.6 is bound, any change in Ca
2+-sensitivity is much less
marked (state RyR212.6*). The model is shown in Figure 6A.
From this model, we derived equations using mass-action
kinetics for the transitions between the various states as shown
below:
dxFree
dt
~k{3x12zk{1x12:6{(k1½FKBP12 zk3½FKBP12:6 )xFree
dx12
dt
~k1½FKBP12 xFreezk{2x 
12{(k{1zk2)x12
dx12:6
dt
~k3½FKBP12:6 xFreezk{4x 
12:6{(k{3zk4)x12:6
dx 
12
dt
~k2x12{k{2x 
12
dx 
12:6
dt
~k4x12:6{k{4x 
12:6
where the probability of the channel dwelling in the state RyR2i
is denoted by xi, where i=Free, 12, 12.6, 12
*, 12.6
*.
Equilibrium approximation with respect to FKBP12 and
FKBP12.6 binding and the subsequent change in Ca
2+-sensitivity
of RyR2 yields:
x 
12~
k2k1k{4k{3½FKBP12 
(k{2k{1k4k3zk{2k{1k{4k3)½FKBP12:6 z(k2k1k{4k{3zk{2k1k{4k{3)½FKBP12 zk{2k{1k{4k{3
x 
12:6~
k{2k{1k4k3½FKBP12:6 
(k{2k{1k4k3zk{2k{1k{4k3)½FKBP12:6 z(k2k1k{4k{3zk{2k1k{4k{3)½FKBP12 zk{2k{1k{4k{3
We modelled the stochastic gating of RyR2 as a continuous-time
Markov process by considering the simplest transition-state
diagram that can describe the kinetics of RyR2 gating between
the closed (C) and open (O) states,
C
 ?
kO
/ 
kC
O
where kO is the rate (probability) of transition from state C to state
O and kC is the rate (probability) of the reverse transition.
In our model, the rate kO depends on the probability that RyR2
is bound to FKBP12 or to FKBP12.6. Of course, the Po of RyR2
channels also depends on other factors such as the cytosolic and
luminal [Ca
2+], on the binding of other closely associated proteins
and on the redox and phosphorylation states of the channels. We
assume, however, that these factors are maintained constant
throughout each experiment since Po remains stable (although
gating is modal [32,35]) over time until the addition of FKBP12 or
FKBP12.6. We therefore include a constant (a), that accounts for
this spontaneous background RyR2 activity. Thus, in the presence
of FK-binding proteins, RyR2 Po is given by the sum of the
probabilities that RyR2 exists in the two possible open states,
namely x12
*+x12.6
*, i.e.
kO~azv, ð1Þ
where, n=x12
*+x12.6
*. The parameter values of the model are
given in Table 1.
The model described above allows us to compute the average
RyR2 Po for various FK-binding protein concentrations and
under different conditions such as the sequential addition of
FKPB12 following FKBP12.6 and vice versa. In choosing parameter
values for the model, as a starting point we used published
estimates of the rate constants of association and dissociation of
FKBP12 and FKBP12.6 to RyR2 [15]. However, in order to
reproduce the FKBP12 concentration-dependence of RyR2 Po
that we observed experimentally together with the obvious slow
dissociation of FKBP12 from RyR2, we found that we needed to
change the binding rates of FKBP12. In this way, we calibrated
the model parameters that are related to the effects of FKBP12 on
RyR2 Po. Figure 6B illustrates the close match between the
simulated data (circles) and the experimental data (triangles).
Our model also allows us to predict how RyR2 gating in the
steady-state would be affected if the experimental protocols shown
in Figures 4A and 4B were applied but the binding of FKBP12 and
FKBP12.6 to RyR2 was allowed to reach equilibrium. This is useful
because the slow dissociation rates of FKBP12 and FKBP12.6 from
RyR2 impose the requirement for hours of steady-state single-
channel recording (for each single-channel) before a true steady-
state equilibrium Po could be calculated. Figures 7A and 7B predict
the equilibrium gating of RyR2 expected under the experimental
conditions of Figure 4A and 4B, respectively.
It hasbeen suggested that there isa reduced amount of FKBP12.6
bound to RyR2 channelsinheartfailure [5,42,43] and thatthisleads
to an increased tendency for SR Ca
2+-release events during diastole
and an increased likelihood of developing arrhythmias. There are
many mechanisms by which this could occur but one possibility
would be that there is simply less FKBP12.6 expressed in the cardiac
cells in heart failure. Our model can predict how changes in cellular
FKBP12.6 levels could affect RyR2 Po at equilibrium if FKBP12
remained at physiological levels (3 mM). We do not know the
physiological level of FKBP12.6 in a cardiac cell except that it is
below detection levels and therefore much lower than the
micromolar levels of FKBP12. Figure 7C predicts the RyR2 Po at
equilibrium for three different concentrations of FKBP12.6 given
thatFKBP12 levelsremain at3 mM.The modelindicates that RyR2
Po at equilibrium would rise in a concentration-dependent manner
as the levels of FKBP12.6 were reduced.
Effects of FK-binding proteins on waves of CICR in
cardiac cells
Although the unresolved controversy over the single-channel
effects of FKBP12.6 [3,8,10,11] is very noticeable in the literature,
Figure 3. Time dependence of the effects of FKBP12 and washout of FKBP12. The data from four different experiments are shown to
illustrate the wide variation in RyR2 Po that occurs over time, even during the control period (before addition of FKBP12). Such shifts in Po (modal
gating) are characteristic of RyR2 channel gating [32,35]. Single-channel records were divided into 10 s segments and the Po of each segment was
calculated. Po was then plotted against time for each experiment. Before addition of FKBP12, channels were activated solely by 10 mM cytosolic Ca
2+.
Typical examples of the effects of 1 pM, 200 nM and 1 mM FKBP12 in the continued presence of 10 mM cytosolic Ca
2+ are shown. The time of
incubation with the indicated FKBP concentration is shown by the bars, as is the time following perfusion of the cytosolic chamber back to control
solutions in order to washout the added FKBP12. The mean data obtained from the steady-state Po changes (recorded for $3 min of continuous
recording) resulting from the addition of FKBP12 at the indicated concentrations are shown in the bar charts to the right of the example Po-time
plots. Po was 0.0460.008 and 0.2360.04 (SEM; n=6; **p,0.01) before and after 1 pM FKBP12, 0.0860.03 and 0.2760.05 (SEM; n=17; **p,0.01)
before and after 200 nM FKBP12 and 0.0960.23 and 0.2360.04 (SEM; n=28; ***p,0.001) before and after 1 mM FKBP12.
doi:10.1371/journal.pone.0031956.g003
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31956there is general agreement with the idea that FKBP12.6 can
‘stabilize’ or reduce cardiac SR Ca
2+-release under pathological
conditions. In heart failure, for example, there is an increased
tendency for the generation of spontaneous waves of SR Ca
2+-
release and the development of delayed after depolarisations
(DADs) [44–48]. Our single-channel experiments, where the
endogenous FKBP’s were displaced prior to experimentation,
demonstrate the effects of FKBP12 and FKBP12.6 on the gating of
RyR2. These data now suggest a possible mechanism by which
FKBP12.6 could act as a ‘stabilizer’ of SR Ca
2+-release in cardiac
cells. FKBP12 would be expected to sensitise RyR2 to a rise in
cytosolic Ca
2+ thereby potentiating CICR. FKBP12.6 would
antagonise this action. We therefore investigated if FKBP12 could
augment spontaneous waves of CICR in rat permeabilised cardiac
myocytes and whether FKBP12.6 could antagonise this effect. At
5 minutes post-permeabilisation, cells were superfused with Fluo-
5F and 234 nM Ca
2+. Figure 8A (top trace) shows the typical
Ca
2+-waves under these conditions. We then perfused with a
physiological concentration of FKBP12 (3 mM) (bottom trace) and
this caused an increase in wave frequency. Figure 8B shows the
mean fluorescence records (measured from the linescans in panel
A) demonstrating that FKBP12 not only increases the frequency of
Ca
2+-waves but also decreases wave amplitude. Figure 8C and D
illustrate the mean wave frequency and mean wave amplitude
before and after superfusion with FKBP12. These results are
exactly what we would expect if RyR2 Po is increased, as similar
effects are observed with other agents, such as caffeine, that
increase RyR2 Po [49].
The reduced wave amplitude may result because there is a
decrease in the SR Ca
2+-content. We examined this by applying
20 mM caffeine to release SR Ca
2+ before and after perfusion with
3 mM FKBP12. Figure 9A demonstrates that 20 mM caffeine
produced a larger Ca
2+-transient in control (3.260.1 DF/Fo) than
in the presence of FKBP12 (2.560.2; n=6; p,0.003) indicating
that there is a reduced SR Ca
2+-content in the presence of
FKBP12.
Our single-channel experiments suggest that FKBP12.6 behaves
as an antagonist of the actions of FKBP12 on RyR2. To
investigate if this mechanism is relevant to SR Ca
2+-release in
cardiac cells we perfused cells with FKBP12.6. The levels of
FKBP12.6 in cardiac cells are so low that they are undetectable
[2,19], hence, unlike FKBP12, we do not know the physiological
concentration. We therefore used 200 nM FKBP12.6, a concen-
tration higher than that likely to be present in a cell. This
concentration of FKBP12.6 did not produce any significant
changes in wave frequency as shown in Figure 9B. To test the
ability of FKBP12.6 to antagonise FKBP12, we first pre-incubated
the cells with 200 nM FKBP12.6 and then perfused with FKBP12
(3 mM) in the presence of 200 nM FKBP12.6. Comparison of the
data in Figure 8C with that in Figure 9B shows that although
FKBP12 still significantly increases wave frequency, pre-incuba-
tion with FKBP12.6 reduces the extent of this effect (FKBP12
alone increases wave frequency by 5060.06% (SEM; n=14;
p#0.001) but after pre-incubation with FKBP12.6, FKBP12 only
increases wave frequency by 16.2560.02% (SEM; n=5;
p=0.002)).
Discussion
We demonstrate that FKBP12 can activate single RyR2
channels at very low concentrations. Like many other activators
of RyR channels including Ca
2+, FKBP12 is a partial agonist. We
also show that FKBP12.6 has no intrinsic ability to reduce RyR2
Po but perhaps may have extremely low efficacy as an activator of
RyR2. It is, however, able to antagonise the effects of FKBP12.
These results suggest that FKBP12 and FKBP12.6 may compete
for the same binding sites on RyR2, especially since both
molecules are structurally so similar. We cannot rule out the
possibility that FKBP12.6 acts to reduce FKBP12-induced
increases in Po by binding at distinct sites although this seems
unlikely since FKBP12.6 does not, alone, reduce the Ca
2+-
activated openings. There has been rather an over-emphasis of the
exclusive nature of FKBP12.6 binding to RyR2 and the possibility
that FKBP12 may affect RyR2 function has been somewhat
overlooked. Our results should not be too unexpected however,
since Jeyakumar et al. (2001) have previously suggested that
FKBP12 binds to the cardiac isoform of many species although
they also indicate that it may not bind to canine RyR2. Seidler et
al. (2007) have also demonstrated binding of GST-FKBP12 to
RyR2. Our reductionist approach has revealed new mechanisms
underlying the functional interactions of FKBP12 and FKBP12.6
with RyR2. This new information may help to resolve the
controversies surrounding the effects of FKBP12.6 on RyR2
channel gating and the many descriptions of the cardiac
‘stabilizing’ properties of FKBP12.6. For example, in models of
heart failure, it has been reported that over-expressing FKBP12.6
[14,16] or introducing molecules of FKBP12.6 that may bind
tighter to RyR2 [50,51], have beneficial effects. Our results suggest
that the beneficial effects of these interventions is not due to the
direct inhibitory action of FKBP12.6, but to the ability of
FKBP12.6 to antagonise the action of FKBP12 as an activator
of RyR2.
The slow rate of dissociation of FKBP12 from RyR2, evidenced
by the washout experiments (Figure 3), means that the binding of
FKBP12 to RyR2 is practically irreversible on the timescale of a
single-channel experiment. This explains the shape of the
concentration-response relationship (Figure 2C) and the high-
affinity of FKBP12 for RyR2. It is thought that there are 4 FKBP
binding sites on each RyR tetramer [2,52] yet it is not known how
many binding sites must be occupied for a functional response.
Our own results also do not provide any clues about the number of
FKBP12 molecules required for an increase in Po. One aspect to
be aware of is that it is very difficult to be sure that all the
endogenous FKBP has been removed before adding back FKBP to
Figure 4. The effects of FKBP12.6 on the ability of FKBP12 to activate RyR2. (A) and (B) are typical examples of experiments where RyR2 Po
was calculated in 10 s segments and plotted against time. (A) Pre-treatment with FKBP12.6 (200 nM). Control recordings were obtained in the
presence of 10 mM cytosolic Ca
2+ as the sole channel activator. As indicated by the bar, 200 nM FKBP12.6 was added to the cytosolic chamber. There
was no obvious change in Po (perhaps a slight increase occurred but notice that Po, on average, remains well below 0.01) following the addition of
200 nM FKBP12.6. The subsequent sequential additions of increasing levels of FKBP12 did not elicit any obvious increases in Po. (B) Post FKBP12-
treatment with FKBP12.6 (200 nM). Control recordings were obtained in the presence of 10 mM cytosolic Ca
2+ as the sole channel activator. The bar
indicates the time of incubation of the channel with 200 nM FKBP12 in the cytosolic chamber. The subsequent addition of 200 nM cytosolic FKBP12.6
(shown by the bar) did not reverse the activating effects of FKBP12. (C) Mean data illustrating that pre-treatment with 200 nM FKBP12.6 (as in the
example shown in (A)), prevents channel activation by FKBP12 (1 mM). (D) Mean data showing that, on average, FKBP12.6 (200 nM) does not reverse
the activation caused by FKBP12 on the timescale of a single-channel experiment, even when Po is monitored for 9 min after adding the FKBP12.6.
Mean values 6 SEM (n$4; *p,0.05) are shown.
doi:10.1371/journal.pone.0031956.g004
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‘below the detection level of a Western blot’ rather than complete
removal of the protein. This is also true for our cardiac membrane
preparations. Although we can ‘deplete’ our cardiac SR of FKBP
with a high salt solution we cannot definitively prove that we have
removed every molecule. However, since exogenously added
FKBP12 always causes a consistent increase in Po, it is clear that,
in our experiments, there are vacant binding sites on RyR2 for
FKBPs that appear to be functionally important. Many studies
have used compounds such as FK506 or rapamycin to lower the
Figure 5. The effects of FKBP12 on open and closed lifetime distributions. The open (right) and closed (left) lifetime distributions and pdfs
from a typical single-channel activated by 10 mMC a
2+ alone (top panel) and from a channel activated by 1 mM cytosolic FKBP12 (bottom panel) are
shown. The best fits to the data were obtained using maximum likelihood fitting. The resulting time constants and percentage areas are shown.
Similar results were obtained in 5 further channels.
doi:10.1371/journal.pone.0031956.g005
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There have been reports, however, that FK506 [53] and
rapamycin [29] directly affect RyR1 gating. We also find that
rapamycin causes very marked activation of RyR2 channels that
appears to be unrelated to the removal of FKBPs (results not
shown) and therefore we have not used these drugs in our study.
Thus, the frequent use of such drugs may have confused our
understanding of the functional effects of FKBPs on RyR channel
gating, adding fuel to any controversy.
We found that the main effect of FKBP12 was to increase the
frequency of channel openings. FKBP12 can also increase the
duration of channel openings but this effect was less pronounced,
probably playing a greater role in the presence of other channel
activators. Since the mechanism by which cytosolic Ca
2+ activates
RyR2 is primarily by increasing the frequency of channel opening
with only a small lengthening of open lifetime durations [35,54] it
is likely that FKBP12 is sensitising RyR2 to cytosolic Ca
2+. Indeed,
the Po of channels that have been activated by FKBP12 can be
reduced to zero when cytosolic Ca
2+ is reduced to sub-activating
levels providing strong evidence for this mechanism of action.
This mechanism of action of FKBP12 is important to consider
when looking at how FKBP12 would influence the opening of
RyR2 channels in situ. In a cardiac cell, we might predict that
FKBP12 would increase the frequency of channel openings during
diastole; a time when RyR2 Po is normally low. Essentially,
FKBP12 would sensitise RyR2 channels to the effects of small rises
in cytosolic Ca
2+ and the channels would become ‘leaky’ during
diastole. This mechanism also provides the best explanation for
the FKBP12-induced increased frequency of spontaneous Ca
2+-
waves that we observe in our permeabilised cell experiments. The
increased wave frequency is associated with a lower SR Ca
2+-
content as shown by Figure 9A. Other activators of RyR2, for
example, caffeine, are also known to increase the frequency of
spontaneous release events and decrease SR Ca
2+-content [49].
This is expected since the SR will be depleted of Ca
2+ following a
spontaneous wave of CICR and the SR must refill before another
wave is possible [27,55]. Normally a wave would not be initiated
before the SR Ca
2+-content was sufficiently recovered. If,
however, RyR2 was sensitised to the effects of cytosolic Ca
2+
(for example, by caffeine or FKBP12), then a wave of CICR would
be triggered at a lower SR Ca
2+-content, reducing the requirement
for the SR to fill. The lower SR Ca
2+-content would give rise to
smaller waves and since less Ca
2+ is released with each wave, the
SR would need less time to refill and so the waves would be more
frequent. Thus, our results can be explained by an effect on RyR2
gating.
Two previous studies have investigated how FKBP12 may affect
SR Ca
2+-release in permeabilised cardiac cells [15,56] but one
study found a decrease in Ca
2+-spark amplitude and width after
perfusion with 1 mM [15] whereas the other study found an
increase in Ca
2+-spark amplitude and width after over-expression
of FKBP12 [56]. These seemingly opposite results highlight the
complex nature of the interactions of FKBPs with RyR2 and
perhaps are due to the particular conditions of the experiments.
For example, Guo et al. (2010) used a fluorescent FKBP12
molecule and the large structural addition may have affected the
functional interaction with RyR2. Seidler et al. (2007) over-
expressed FKBP12 and therefore before cell permeabilisation it
would be expected that a greater than physiological level of
FKBP12 would bind to RyR2 channels. After cell permeabilisa-
tion, since there was no added FKBP in the perfusate, it would be
Figure 6. A mechanism to describe the influence of FK-binding
proteins on RyR2 gating. (A) Proposed schematic representation of
the interactions of FK-binding proteins with RyR2. RyR2Free represents
the RyR2 channel state when no FK-binding proteins are bound. RyR212
and RyR212.6 represent the states of the channel following the binding
of either FKBP12 or FKBP12.6. RyR212
* and RyR212.6
* represent the
altered conformations of RyR2 that result from the tight binding to
FKBP12 or FKBP12.6, respectively, and give rise to a change in the Ca
2+-
sensitivity of RyR2. (B) Model derived FKBP12 concentration-response
relationship showing RyR2 Po following addition of various concentra-
tions of FKBP12. Steady state Po values were computed by taking a trial
average over 100 Monte Carlo simulations of a single channel (circles).
According to the fit, the model predicts the EC50 for FKBP12=0.12 pM.
As a comparison, the mean Po values obtained from the experimental
data at 1 pM, 200 nM and 1 mM FKBP12 have also been plotted
(triangles; error bars are SEM) Parameter values used in the simulations
are given in Table 1.
doi:10.1371/journal.pone.0031956.g006
Table 1. Parameter values of the RyR2 model.
Parameter values of the RyR2 model
kC=480s
21 a=0.005
k1=0.29610
2 mM
21 s
21 k21=6.11610
26 s
21
k2=0.03 s
21 k22=0.18 s
21
k3=0.33610
6 mM
21 s
21 k23=4.2610
24 s
21
k4=0.001 s
21 k24=0.25 s
21
Parameter values used in the model simulations shown in Figures 6 and 7. We
used a previously published estimate of the rate of dissociation of FKBP12.6
from RyR2 (k23=4.2610
24 s
21) [15] but all other values were were chosen to
ensure that the model reproduces all our experimental data. The value of kO is
given by Equation (1).
doi:10.1371/journal.pone.0031956.t001
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PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31956Figure7. Model predictionsofRyR2PoatequilibriuminthepresenceofbothFKBP12and FKBP12.6.Modelpredictions ofRyR2 equilibrium
Po for the combinations of FKBP12 and FKBP12.6 that are present in the experiments detailed in Figure 4. Panels A and B show the predicted Po at
equilibrium of a typical RyR2 channel under the experimental conditions shown in Figures 4A and 4B, respectively. Whereas the single-channel
experiments(Figure4)which,onaverage,runfor approximately 20 min, typically reflecttheeffects ofthe protein that boundfirst (sincedissociationrates
of FKBP12 and 12.6 are so slow), the model allows us to predict what would happen at equilibrium. (C) Model predictions of equilibrium RyR2 Po if
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PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e31956FKBP12.6 levels vary while FKBP12 is maintained at a physiological level of 3 mM. Steady-state Po values at equilibrium have been computed by taking a
trial average over 100 Monte Carlo simulations of a single RyR2 channel. The parameter values used in the simulations are given in Table 1.
doi:10.1371/journal.pone.0031956.g007
Figure 8. FKBP12 causes an increase in Ca
2+-wave frequency. (A) Linescan images collected from permeabilised cardiac myocytes under
control conditions (top), and in the presence of 3 mM FKBP12 (below). (B) Mean fluorescence records from the linescans shown in panel A. (C)
illustrates the mean change in frequency caused by 3 mM FKBP12 (SEM; n=14; ***p#0.001) and (D) shows the effect of 3 mM FKBP12 on wave
amplitude (SEM; n=14; *p=0.028).
doi:10.1371/journal.pone.0031956.g008
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PLoS ONE | www.plosone.org 13 February 2012 | Volume 7 | Issue 2 | e31956expected that there would be a lower than physiological level of
FKBP12 molecules associated with RyR2 since FKBP12 would be
lost in the perfusate. In the light of our results, it is interesting to
consider how endogenous FKBP12 would influence RyR2
behaviour in the FKBP12.6 knockout mouse model [17]. Ca
2+-
spark amplitude and duration are increased in cardiac cells
isolated from the FKBP12.6 knockout and it is suggested that the
RyR channels are open for longer [17]. This is what might be
expected if the activatory effects of FKBP12 were left uncon-
strained by the antagonistic effects of FKBP12.6.
Our results suggest that the relative levels of FKBP12 and
FKBP12.6 in a cardiac cell will be important in the regulation of
SR Ca
2+-release since FKBP12.6 can inhibit the effects of
FKBP12. This is confirmed by mathematical modelling of our
data (Figure 7C). For example, any lowering in the expression
levels of FKBP12.6 may swing the balance of FKBP12/FKBP12.6
binding to RyR2 to a level where RyR2 sensitivity for cytosolic
Ca
2+ is increased. This would promote a greater tendency for the
development of spontaneous waves of CICR and delayed after
depolarisations (DADs) and an increased likelihood of fatal
arrhythmias. A model of this scheme is shown in Figure 10.
There has been much controversy over the idea that FKBP12.6
acts as a natural ‘stabiliser’ of RyR2 activity in cardiac cells and
that in heart failure there is a lower level of FKBP12.6 associated
with RyR2 [5,11,43,57–59]. Much of the controversy arose
because many groups, including our own, were not able to find
any evidence that FKBP12.6 could reduce the Po of RyR2. Our
work now reconciles these apparent inconsistencies and shows that
FKBP12.6 can lower RyR2 Po indirectly by antagonising the
activating effects of FKBP12. The many cellular changes that
Figure 9. FKBP12 (3 mM) reduces SR Ca
2+-content. (A) Typical changes in fluorescence following caffeine addition are shown for the same cell
in control conditions (left) and in the presence of FKBP12 (3 mM) (right). Caffeine (20 mM) was applied for the period shown by the solid bars. (B)
shows the effects of FKBP12.6 (200 nM) on wave frequency. Data from Figure 8C (rightmost two bars) is included so that the effects of FKBP12 in the
absence and presence of added FKBP12.6 can be directly compared. Pre-treatment with 200 nM FKBP12.6 reduces the effect of FKBP12 (3 mM) on
Ca
2+- wave frequency. FKBP12.6 (200 nM) alone has no effect on wave frequency. The FKBP12.6 percentage increase in wave
frequency=16.2560.021% (SEM; n=5; **p=0.002). The FKBP12 percentage increase in wave frequency=5060.058% (SEM; n=14; ***p#0.001).
Values are normalised to the relevant control.
doi:10.1371/journal.pone.0031956.g009
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PLoS ONE | www.plosone.org 14 February 2012 | Volume 7 | Issue 2 | e31956occur in heart failure could lead to changes in the ratio of
FKBP12.6/FKBP12 levels in cardiac cells or to conformational
changes to RyR2 that affect the relative affinity/efficacy of
FKBP12 or FKBP12.6. Such changes could directly impinge on
SR Ca
2+-release and could lead to the ‘leaky’ RyR2 channels,
reduced SR Ca
2+-load and increased likelihood of arrhythmias
that occur in heart failure.
Supporting Information
Figure S1 The effects of high salt incubation on the
association of FKBPs with cardiac mixed membrane
(MM) vesicles. Western blot analysis following incubation of
cardiac mixed membrane vesicles with a high sucrose (0.4 M)
solution (left lane) or a high salt (0.4 M) solution (right lane).
Vesicles were loaded at 100 mg. Western blots were probed with
an anti-FKBP12 antibody (recognising both FKBP12 and
FKBP12.6). Size markers are indicated in kDa.
(TIFF)
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